David M. Clapper

SurgRx, Inc. develops tissue sealing and cutting technology. The company's products include EnSeal, TRIO, PowerTip, RF-60, and universal RF Generator. It also develops vessel fusion system used in electrosurgical devices. The company was founded in 2001 and is headquartered in Redwood City, CA.

CYTYC Surgical Products was founded to design, develop, manufacture and market innovative therapeutic devices that improve the quality of women's healthcare in a cost- effective manner. Its initial product, the Novasure Endometrial Ablation System, is used to treat women who suffer from excessive menstrual bleeding.

Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA.

SurgRx, Inc. develops tissue sealing and cutting technology. The company's products include EnSeal, TRIO, PowerTip, RF-60, and universal RF Generator. It also develops vessel fusion system used in electrosurgical devices. The company was founded in 2001 and is headquartered in Redwood City, CA.

CYTYC Surgical Products was founded to design, develop, manufacture and market innovative therapeutic devices that improve the quality of women's healthcare in a cost- effective manner. Its initial product, the Novasure Endometrial Ablation System, is used to treat women who suffer from excessive menstrual bleeding.

Conor Medsystems LLC develops vascular drug delivery technologies. Its products include controlled vascular drug delivery technologies and novel stent that are used in the treatment of coronary artery disease and delivery of a broad spectrum of therapeutic agents. The company was founded by John F. Shanley in 1999 and is headquartered in Menlo Park, CA.

Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA.

DFINE, Inc.engages in the development and commercialization of medical device system for treating vertebral compression fractures. The company was founded by John H. Shadduck and Csaba Truckai in 2004 and is headquartered in South Jordan, UT.

Focal Inc, is a developing biodegradable interventional therapeutic products to treat serious local diseases. The company products consist of a biodegradable polymer system that can deliver drugs locally to the site of disease and/or act as a physical barrier. Other Focal research & development programs include polymer and drug delivery products to: prevent adhesions (internal scar tissue) following surgery; serve as surgical sealants; and deliver drugs locally for other indications.

DFINE, Inc.engages in the development and commercialization of medical device system for treating vertebral compression fractures. The company was founded by John H. Shadduck and Csaba Truckai in 2004 and is headquartered in South Jordan, UT.

Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA.

Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA.